<!DOCTYPE html><html lang="en-us" >

<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  
  
  
    <meta name="generator" content="Wowchemy 5.2.0 for Hugo" />
  

  

  
  
  
  
  
    
    
    
  
  

  <meta name="author" content="Qi Zhao" />

  
  
  
    
  
  <meta name="description" content="Objectives: Anti-PD-1 immune checkpoint blockade represents the onset of a new era in cancer immunotherapy. However, robust predictors are necessary for screening patients with immune checkpoint-responsive oesophageal squamous cell carcinoma (ESCC).
Methods: We obtained biopsy samples from an ESCC patient with mixed responses. The expression of CD4, CD8, CD68, PD-L1, RBPJL and IL-16 was analysed by immunohistochemistry, and the correlation with prognostic value was obtained from the GEPIA portal. T-cell functions were examined by flow cytometry, MTS and transwell assays. The secreted cytokines were identified using an Inflammation Array Kit. The concentration of soluble IFN-γ was measured by enzyme-linked immunosorbent assay. The clinical benefit of RBPJL was examined in a PBMC xenograft mouse model.
Results: The patient had an exceptional clinical response with shrinkage of the primary oesophageal and lung metastatic lesions as well as enlargement of liver metastatic lesions after toripalimab monotherapy. Four liver-specific gene mutations were identified. RBPJL showed better response to toripalimab in the PBMC cell-derived xenograft (CDX) ESCC model. Conditional medium from RBPJL overexpression induced chemotaxis and proliferation of T lymphocytes, as well as Th2/Th1 differentiation through the RBPJL-NF-κB-IL-16 axis in vitro. These functions were all inhibited by the p.P476S mutation of RBPJL (RBPJL (p.P476S)).
Conclusions: We report for the first time that RBPJL (p.P476S) promotes tumor growth in ESCC and inhibits the efficacy of anti-PD-1 therapy through blunting T-cell responses. Our findings provide a potential new predictor for evaluating the efficacy of anti-PD-1 therapy in ESCC patients." />

  
  <link rel="alternate" hreflang="en-us" href="https://likelet.github.io/publication/journal-article-p476s/" />

  







  




  
  
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin />
  

  
  
  
    <meta name="theme-color" content="#1565c0" />
  

  
  

  
  
  
  
    
    
      <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/academicons/1.9.0/css/academicons.min.css" integrity="sha512-W4yqoT1+8NLkinBLBZko+dFB2ZbHsYLDdr50VElllRcNt2Q4/GSs6u71UHKxB7S6JEMCp5Ve4xjh3eGQl/HRvg==" crossorigin="anonymous">
    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.14.0/css/all.min.css" integrity="sha256-FMvZuGapsJLjouA6k7Eo2lusoAX9i0ShlWFG6qt7SLc=" crossorigin="anonymous">

    
    

    
    
    
      
    
    

    
    
    
      <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/leaflet/1.7.1/leaflet.min.css" integrity="sha512-1xoFisiGdy9nvho8EgXuXvnpR5GAMSjFwp40gSRE3NwdUdIMIKuPa7bqoUhLD0O/5tPNhteAsE5XyyMi5reQVA==" crossorigin="anonymous" media="print" onload="this.media='all'">
    

    

    
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      
        
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
  

  
  
  
    
      
      
      <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Lato:400,700%7CMerriweather%7CRoboto+Mono&display=swap">
      
    
  

  
  
  
  
  
  <link rel="stylesheet" href="/css/wowchemy.84f6d3f2750c6dae1259b2f1b92da214.css" />

  



  

  

  




  
  
  

  

  
    <link rel="manifest" href="/index.webmanifest" />
  

  <link rel="icon" type="image/png" href="/media/icon_huc92b86c516357a0134b7c1ec7b6a518b_64366_32x32_fill_lanczos_center_3.png" />
  <link rel="apple-touch-icon" type="image/png" href="/media/icon_huc92b86c516357a0134b7c1ec7b6a518b_64366_180x180_fill_lanczos_center_3.png" />

  <link rel="canonical" href="https://likelet.github.io/publication/journal-article-p476s/" />

  
  
  
  
  
  
  
  
    
    
  
  
  <meta property="twitter:card" content="summary" />
  
  <meta property="og:site_name" content="Qizhao Lab" />
  <meta property="og:url" content="https://likelet.github.io/publication/journal-article-p476s/" />
  <meta property="og:title" content="p.P476S mutation of RBPJL inhibits the efficacy of anti-PD-1 therapy in oesophageal squamous cell carcinoma by blunting T-cell responses&#34; | Qizhao Lab" />
  <meta property="og:description" content="Objectives: Anti-PD-1 immune checkpoint blockade represents the onset of a new era in cancer immunotherapy. However, robust predictors are necessary for screening patients with immune checkpoint-responsive oesophageal squamous cell carcinoma (ESCC).
Methods: We obtained biopsy samples from an ESCC patient with mixed responses. The expression of CD4, CD8, CD68, PD-L1, RBPJL and IL-16 was analysed by immunohistochemistry, and the correlation with prognostic value was obtained from the GEPIA portal. T-cell functions were examined by flow cytometry, MTS and transwell assays. The secreted cytokines were identified using an Inflammation Array Kit. The concentration of soluble IFN-γ was measured by enzyme-linked immunosorbent assay. The clinical benefit of RBPJL was examined in a PBMC xenograft mouse model.
Results: The patient had an exceptional clinical response with shrinkage of the primary oesophageal and lung metastatic lesions as well as enlargement of liver metastatic lesions after toripalimab monotherapy. Four liver-specific gene mutations were identified. RBPJL showed better response to toripalimab in the PBMC cell-derived xenograft (CDX) ESCC model. Conditional medium from RBPJL overexpression induced chemotaxis and proliferation of T lymphocytes, as well as Th2/Th1 differentiation through the RBPJL-NF-κB-IL-16 axis in vitro. These functions were all inhibited by the p.P476S mutation of RBPJL (RBPJL (p.P476S)).
Conclusions: We report for the first time that RBPJL (p.P476S) promotes tumor growth in ESCC and inhibits the efficacy of anti-PD-1 therapy through blunting T-cell responses. Our findings provide a potential new predictor for evaluating the efficacy of anti-PD-1 therapy in ESCC patients." /><meta property="og:image" content="https://likelet.github.io/media/icon_huc92b86c516357a0134b7c1ec7b6a518b_64366_512x512_fill_lanczos_center_3.png" />
    <meta property="twitter:image" content="https://likelet.github.io/media/icon_huc92b86c516357a0134b7c1ec7b6a518b_64366_512x512_fill_lanczos_center_3.png" /><meta property="og:locale" content="en-us" />
  
    
      <meta
        property="article:published_time"
        content="2020-09-01T00:00:00&#43;00:00"
      />
    
    <meta property="article:modified_time" content="2020-09-01T00:00:00&#43;00:00">
  

  


    









<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "Article",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://likelet.github.io/publication/journal-article-p476s/"
  },
  "headline": "p.P476S mutation of RBPJL inhibits the efficacy of anti-PD-1 therapy in oesophageal squamous cell carcinoma by blunting T-cell responses\"",
  
  "datePublished": "2020-09-01T00:00:00Z",
  "dateModified": "2020-09-01T00:00:00Z",
  
  "author": {
    "@type": "Person",
    "name": "Lei Miao"
  },
  
  "publisher": {
    "@type": "Organization",
    "name": "Qizhao Lab",
    "logo": {
      "@type": "ImageObject",
      "url": "https://likelet.github.io/media/icon_huc92b86c516357a0134b7c1ec7b6a518b_64366_192x192_fill_lanczos_center_3.png"
    }
  },
  "description": "Objectives: Anti-PD-1 immune checkpoint blockade represents the onset of a new era in cancer immunotherapy. However, robust predictors are necessary for screening patients with immune checkpoint-responsive oesophageal squamous cell carcinoma (ESCC).\nMethods: We obtained biopsy samples from an ESCC patient with mixed responses. The expression of CD4, CD8, CD68, PD-L1, RBPJL and IL-16 was analysed by immunohistochemistry, and the correlation with prognostic value was obtained from the GEPIA portal. T-cell functions were examined by flow cytometry, MTS and transwell assays. The secreted cytokines were identified using an Inflammation Array Kit. The concentration of soluble IFN-γ was measured by enzyme-linked immunosorbent assay. The clinical benefit of RBPJL was examined in a PBMC xenograft mouse model.\nResults: The patient had an exceptional clinical response with shrinkage of the primary oesophageal and lung metastatic lesions as well as enlargement of liver metastatic lesions after toripalimab monotherapy. Four liver-specific gene mutations were identified. RBPJL showed better response to toripalimab in the PBMC cell-derived xenograft (CDX) ESCC model. Conditional medium from RBPJL overexpression induced chemotaxis and proliferation of T lymphocytes, as well as Th2/Th1 differentiation through the RBPJL-NF-κB-IL-16 axis in vitro. These functions were all inhibited by the p.P476S mutation of RBPJL (RBPJL (p.P476S)).\nConclusions: We report for the first time that RBPJL (p.P476S) promotes tumor growth in ESCC and inhibits the efficacy of anti-PD-1 therapy through blunting T-cell responses. Our findings provide a potential new predictor for evaluating the efficacy of anti-PD-1 therapy in ESCC patients."
}
</script>

  

  

  

  





  <title>p.P476S mutation of RBPJL inhibits the efficacy of anti-PD-1 therapy in oesophageal squamous cell carcinoma by blunting T-cell responses&#34; | Qizhao Lab</title>
</head>


<body id="top" data-spy="scroll" data-offset="70" data-target="#TableOfContents" class="page-wrapper   " data-wc-page-id="bb61e6eefc47202d1ee128b13b128988" >

  
  
  
  
  
  
  
  
  
  <script src="/js/wowchemy-init.min.c2ae95842e5b33a787c7b8c567e989a4.js"></script>

  


<aside class="search-modal" id="search">
  <div class="container">
    <section class="search-header">

      <div class="row no-gutters justify-content-between mb-3">
        <div class="col-6">
          <h1>Search</h1>
        </div>
        <div class="col-6 col-search-close">
          <a class="js-search" href="#" aria-label="Close"><i class="fas fa-times-circle text-muted" aria-hidden="true"></i></a>
        </div>
      </div>

      <div id="search-box">
        
        <input name="q" id="search-query" placeholder="Search..." autocapitalize="off"
        autocomplete="off" autocorrect="off" spellcheck="false" type="search" class="form-control"
        aria-label="Search...">
        
      </div>

      
      

      

    </section>
    <section class="section-search-results">

      <div id="search-hits">
        
      </div>

    </section>
  </div>
</aside>



  <div class="page-header">
    












<nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id="navbar-main">
  <div class="container-xl">

    
    <div class="d-none d-lg-inline-flex">
      <a class="navbar-brand" href="/">Qizhao Lab</a>
    </div>
    

    
    <button type="button" class="navbar-toggler" data-toggle="collapse"
            data-target="#navbar-content" aria-controls="navbar-content" aria-expanded="false" aria-label="Toggle navigation">
    <span><i class="fas fa-bars"></i></span>
    </button>
    

    
    <div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none">
      <a class="navbar-brand" href="/">Qizhao Lab</a>
    </div>
    

    
    
    <div class="navbar-collapse main-menu-item collapse justify-content-end" id="navbar-content">

      
      <ul class="navbar-nav d-md-inline-flex">
        

        

        
        
        

        

        
        
        
        

        
          
            
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/post"><span>News</span></a>
        </li>

        
        

        

        
        
        
          
        

        

        
        
        
        

        
          
            
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/people"><span>People</span></a>
        </li>

        
        

        

        
        
        
          
        

        

        
        
        
        

        
          
            
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/publication"><span>Publications</span></a>
        </li>

        
        

        

        
        
        
          
        

        

        
        
        
        

        
          
            
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/contact"><span>Contact</span></a>
        </li>

        
        

      

        
      </ul>
    </div>

    <ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2">

      
      
        
      

      
      
      <li class="nav-item">
        <a class="nav-link js-search" href="#" aria-label="Search"><i class="fas fa-search" aria-hidden="true"></i></a>
      </li>
      

      
      

      
      

    </ul>

  </div>
</nav>


  </div>

  <div class="page-body">
    








<div class="pub">

  












  

  
  
  
<div class="article-container pt-3">
  <h1>p.P476S mutation of RBPJL inhibits the efficacy of anti-PD-1 therapy in oesophageal squamous cell carcinoma by blunting T-cell responses&#34;</h1>

  

  
    


<div class="article-metadata">

  
  
  
  
  <div>
    

  <span >
      <a href="/author/lei-miao/">Lei Miao</a></span>, <span >
      <a href="/author/xiao-li-wei/">Xiao-Li Wei</a></span>, <span >
      <a href="/author/qi-zhao/">Qi Zhao</a></span>, <span >
      <a href="/author/jingjing-qi/">JingJing Qi</a></span>, <span >
      <a href="/author/chao-ren/">Chao Ren</a></span>, <span >
      <a href="/author/qi-nian-wu/">Qi-nian Wu</a></span>, <span >
      <a href="/author/da-liang-wei/">Da-Liang Wei</a></span>, <span >
      <a href="/author/jia-liu/">Jia Liu</a></span>, <span >
      <a href="/author/feng-hua-wang/">Feng-Hua Wang</a></span>, <span >
      <a href="/author/rui-hua-xu/">Rui-hua Xu</a></span>
  </div>
  
  

  
  <span class="article-date">
    
    
      
    
    September 2020
  </span>
  

  

  

  
  
  
  
  
  

  
  

</div>

    




<div class="btn-links mb-3">
  
  








  





<a href="#" class="btn btn-outline-primary btn-page-header js-cite-modal"
        data-filename="/publication/journal-article-p476s/cite.bib">
  Cite
</a>





  
    
  









<a class="btn btn-outline-primary btn-page-header" href="https://doi.org/10.1002/cti2.1172" target="_blank" rel="noopener">
  DOI
</a>



</div>


  
</div>



  <div class="article-container">

    
    <h3>Abstract</h3>
    <p class="pub-abstract">Objectives: Anti-PD-1 immune checkpoint blockade represents the onset of a new era in cancer immunotherapy. However, robust predictors are necessary for screening patients with immune checkpoint-responsive oesophageal squamous cell carcinoma (ESCC).
Methods: We obtained biopsy samples from an ESCC patient with mixed responses. The expression of CD4, CD8, CD68, PD-L1, RBPJL and IL-16 was analysed by immunohistochemistry, and the correlation with prognostic value was obtained from the GEPIA portal. T-cell functions were examined by flow cytometry, MTS and transwell assays. The secreted cytokines were identified using an Inflammation Array Kit. The concentration of soluble IFN-γ was measured by enzyme-linked immunosorbent assay. The clinical benefit of RBPJL was examined in a PBMC xenograft mouse model.
Results: The patient had an exceptional clinical response with shrinkage of the primary oesophageal and lung metastatic lesions as well as enlargement of liver metastatic lesions after toripalimab monotherapy. Four liver-specific gene mutations were identified. RBPJL showed better response to toripalimab in the PBMC cell-derived xenograft (CDX) ESCC model. Conditional medium from RBPJL overexpression induced chemotaxis and proliferation of T lymphocytes, as well as Th2/Th1 differentiation through the RBPJL-NF-κB-IL-16 axis in vitro. These functions were all inhibited by the p.P476S mutation of RBPJL (RBPJL (p.P476S)).
Conclusions: We report for the first time that RBPJL (p.P476S) promotes tumor growth in ESCC and inhibits the efficacy of anti-PD-1 therapy through blunting T-cell responses. Our findings provide a potential new predictor for evaluating the efficacy of anti-PD-1 therapy in ESCC patients.</p>
    

    
    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Type</div>
          <div class="col-12 col-md-9">
            <a href="/publication/#2">
              Journal article
            </a>
          </div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Publication</div>
          <div class="col-12 col-md-9">Clinical Translational Immunology</div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    <div class="space-below"></div>

    <div class="article-style"><div class="alert alert-note">
  <div>
    Click the <em>Cite</em> button above to demo the feature to enable visitors to import publication metadata into their reference management software.
  </div>
</div>
<p>Supplementary notes can be added here, including <a href="https://sourcethemes.com/academic/docs/writing-markdown-latex/" target="_blank" rel="noopener">code and math</a>.</p>
</div>

    




<div class="article-tags">
  
  <a class="badge badge-light" href="/tag/source-themes/">Source Themes</a>
  
</div>



<div class="share-box" aria-hidden="true">
  <ul class="share">
    
      
      
      
        
      
      
      
      <li>
        <a href="https://twitter.com/intent/tweet?url=https://likelet.github.io/publication/journal-article-p476s/&amp;text=p.P476S%20mutation%20of%20RBPJL%20inhibits%20the%20efficacy%20of%20anti-PD-1%20therapy%20in%20oesophageal%20squamous%20cell%20carcinoma%20by%20blunting%20T-cell%20responses&amp;#34;" target="_blank" rel="noopener" class="share-btn-twitter">
          <i class="fab fa-twitter"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="https://www.facebook.com/sharer.php?u=https://likelet.github.io/publication/journal-article-p476s/&amp;t=p.P476S%20mutation%20of%20RBPJL%20inhibits%20the%20efficacy%20of%20anti-PD-1%20therapy%20in%20oesophageal%20squamous%20cell%20carcinoma%20by%20blunting%20T-cell%20responses&amp;#34;" target="_blank" rel="noopener" class="share-btn-facebook">
          <i class="fab fa-facebook"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="mailto:?subject=p.P476S%20mutation%20of%20RBPJL%20inhibits%20the%20efficacy%20of%20anti-PD-1%20therapy%20in%20oesophageal%20squamous%20cell%20carcinoma%20by%20blunting%20T-cell%20responses&amp;#34;&amp;body=https://likelet.github.io/publication/journal-article-p476s/" target="_blank" rel="noopener" class="share-btn-email">
          <i class="fas fa-envelope"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="https://www.linkedin.com/shareArticle?url=https://likelet.github.io/publication/journal-article-p476s/&amp;title=p.P476S%20mutation%20of%20RBPJL%20inhibits%20the%20efficacy%20of%20anti-PD-1%20therapy%20in%20oesophageal%20squamous%20cell%20carcinoma%20by%20blunting%20T-cell%20responses&amp;#34;" target="_blank" rel="noopener" class="share-btn-linkedin">
          <i class="fab fa-linkedin-in"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="whatsapp://send?text=p.P476S%20mutation%20of%20RBPJL%20inhibits%20the%20efficacy%20of%20anti-PD-1%20therapy%20in%20oesophageal%20squamous%20cell%20carcinoma%20by%20blunting%20T-cell%20responses&amp;#34;%20https://likelet.github.io/publication/journal-article-p476s/" target="_blank" rel="noopener" class="share-btn-whatsapp">
          <i class="fab fa-whatsapp"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="https://service.weibo.com/share/share.php?url=https://likelet.github.io/publication/journal-article-p476s/&amp;title=p.P476S%20mutation%20of%20RBPJL%20inhibits%20the%20efficacy%20of%20anti-PD-1%20therapy%20in%20oesophageal%20squamous%20cell%20carcinoma%20by%20blunting%20T-cell%20responses&amp;#34;" target="_blank" rel="noopener" class="share-btn-weibo">
          <i class="fab fa-weibo"></i>
        </a>
      </li>
    
  </ul>
</div>











  
  
    




  
    




  
    



  
  
  
  
  
  <div class="media author-card content-widget-hr">
    
      
      <a href="/author/qi-zhao/"><img class="avatar mr-3 avatar-circle" src="/author/qi-zhao/avatar_hubfa6ca2e6c68587649f1935fb1a2bafd_156692_270x270_fill_lanczos_center_3.png" alt="Qi Zhao"></a>
    

    <div class="media-body">
      <h5 class="card-title"><a href="/author/qi-zhao/">Qi Zhao</a></h5>
      <h6 class="card-subtitle">Associate Professor of Cancer Bioinformatics</h6>
      <p class="card-text">Qi Zhao is an assistant professor of cancer bioinfomatics at the Sun Yat-sen university cancer center. His research interests include cancer genomics, biosoftware development and high performance computing.</p>
      <ul class="network-icon" aria-hidden="true">
  
    
    
    
      
    
    
    
    
    
    <li>
      <a href="mailto:zhaoqi@sysucc.org.cn" >
        <i class="fas fa-envelope"></i>
      </a>
    </li>
  
    
    
    
      
    
    
    
    
    
      
    
    <li>
      <a href="https://twitter.com/qi_likelet" target="_blank" rel="noopener">
        <i class="fab fa-twitter"></i>
      </a>
    </li>
  
    
    
    
    
    
    
    
      
    
    <li>
      <a href="https://scholar.google.co.uk/citations?user=j7LCthMAAAAJ" target="_blank" rel="noopener">
        <i class="ai ai-google-scholar"></i>
      </a>
    </li>
  
    
    
    
      
    
    
    
    
    
      
    
    <li>
      <a href="https://github.com/gcushen" target="_blank" rel="noopener">
        <i class="fab fa-github"></i>
      </a>
    </li>
  
</ul>

    </div>
  </div>


  
    




  
    




  
    




  
    




  
    




  
    




  
    




  














  
  
  <div class="article-widget content-widget-hr">
    <h3>Related</h3>
    <ul>
      
      <li><a href="/publication/journal-article-novel/">Novel Genetic and Epigenetic Biomarkers of Prognostic and Predictive Significance in Stage II/III Colorectal Cancer</a></li>
      
      <li><a href="/publication/journal-article-rmvar/">RMVar: an updated database of functional variants involved in RNA modifications</a></li>
      
      <li><a href="/publication/journal-article-systematic-analysis/">Systematic analysis of the transcriptome in small‐cell carcinoma of the oesophagus reveals its immune microenvironment</a></li>
      
      <li><a href="/publication/journal-article-targeting/">Targeting the STING pathway in tumor-associated macrophages regulates innate immune sensing of gastric cancer cells</a></li>
      
      <li><a href="/publication/journal-article-crossicc/">CrossICC: iterative consensus clustering of cross-platform gene expression data without adjusting batch effect</a></li>
      
    </ul>
  </div>
  





  </div>
</div>
  </div>

  <div class="page-footer">
    
    
    <div class="container">
      <footer class="site-footer">

  

  

  

  
  






  <p class="powered-by">
    
    
    
      
      
      
      
      
      
      Published with <a href="https://wowchemy.com/?utm_campaign=poweredby" target="_blank" rel="noopener">Wowchemy</a> — the free, <a href="https://github.com/wowchemy/wowchemy-hugo-modules" target="_blank" rel="noopener">open source</a> website builder that empowers creators.
    
  </p>
</footer>

    </div>
    
  </div>

  
<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <h5 class="modal-title">Cite</h5>
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">&times;</span>
        </button>
      </div>
      <div class="modal-body">
        <pre><code class="tex hljs"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-outline-primary my-1 js-copy-cite" href="#" target="_blank">
          <i class="fas fa-copy"></i> Copy
        </a>
        <a class="btn btn-outline-primary my-1 js-download-cite" href="#" target="_blank">
          <i class="fas fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

      

    
    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.5.1/jquery.min.js" integrity="sha256-9/aliU8dGd2tb6OSsuzixeV4y/faTqgFtohetphbbj0=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/instant.page/5.1.0/instantpage.min.js" integrity="sha512-1+qUtKoh9XZW7j+6LhRMAyOrgSQKenQ4mluTR+cvxXjP1Z54RxZuzstR/H9kgPXQsVB8IW7DMDFUJpzLjvhGSQ==" crossorigin="anonymous"></script>

      
      
        <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.4/imagesloaded.pkgd.min.js" integrity="sha256-lqvxZrPLtfffUl2G/e7szqSvPBILGbwmsGE1MKlOi0Q=" crossorigin="anonymous"></script>
        <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.6/isotope.pkgd.min.js" integrity="sha256-CBrpuqrMhXwcLLUd5tvQ4euBHCdh7wGlDfNz8vbu/iI=" crossorigin="anonymous"></script>
      

      
      

      

      

    

    
    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/leaflet/1.7.1/leaflet.min.js" integrity="sha512-SeiQaaDh73yrb56sTW/RgVdi/mMqNeM2oBwubFHagc5BkixSpP1fvqF47mKzPGWYSSy4RwbBunrJBQ4Co8fRWA==" crossorigin="anonymous"></script>
    

    
    

    
    
    
      
      <script id="search-hit-fuse-template" type="text/x-template">
        <div class="search-hit" id="summary-{{key}}">
          <div class="search-hit-content">
            <div class="search-hit-name">
              <a href="{{relpermalink}}">{{title}}</a>
              <div class="article-metadata search-hit-type">{{type}}</div>
              <p class="search-hit-description">{{snippet}}</p>
            </div>
          </div>
        </div>
      </script>
      
        <script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/3.2.1/fuse.min.js" integrity="sha256-VzgmKYmhsGNNN4Ph1kMW+BjoYJM2jV5i4IlFoeZA9XI=" crossorigin="anonymous"></script>
        <script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/jquery.mark.min.js" integrity="sha256-4HLtjeVgH0eIB3aZ9mLYF6E8oU5chNdjU6p6rrXpl9U=" crossorigin="anonymous"></script>
      
    

    
    

    
    
    
    

    
    <script src="/js/bootstrap.bundle.min.6aed84840afc03ab4d5750157f69c120.js"></script>

    
    
      
      
      
      
      
      
      
    

    
    
    
    
    
    
    
    
      
      
    
    
    <script src="/en/js/wowchemy.min.fb8eb32a4d207f5f18023712a904b210.js"></script>

    






</body>
</html>
